Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Bevacizumab both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion secondary trial: FFDM and DBT CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion secondary trial: FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion secondary trial: FFDM Only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion secondary trial: FFDM exam only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion inflation with carbon dioxide by remote control secondary trial: FFDM and DBT CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion inflation with carbon dioxide by remote control secondary trial: FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion inflation with carbon dioxide by remote control secondary trial: FFDM Only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion inflation with carbon dioxide by remote control secondary trial: FFDM exam only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander. secondary trial: FFDM and DBT CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander. secondary trial: FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander. secondary trial: FFDM Only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander. secondary trial: FFDM exam only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion secondary trial: FFDM and DBT CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion secondary trial: FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion secondary trial: FFDM Only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion secondary trial: FFDM exam only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion inflated by needle injections of saline secondary trial: FFDM and DBT CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion inflated by needle injections of saline secondary trial: FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion inflated by needle injections of saline secondary trial: FFDM Only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion inflated by needle injections of saline secondary trial: FFDM exam only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline. secondary trial: FFDM and DBT CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline. secondary trial: FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline. secondary trial: FFDM Only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
f79a9011-0a68-4255-a40f-5d73af412bf0 | primary trial: Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline. secondary trial: FFDM exam only CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Total: 31/116 (26.72%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Neutropenia 1/116 (0.86%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Thrombocytopenia 1/116 (0.86%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Acute myocardial infarction 1/116 (0.86%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Myocardial infarction 0/116 (0.00%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Pericardial effusion 0/116 (0.00%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Febrile Neutropenia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Retinopathy Hypertensive 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Febrile Infection 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Postoperative Wound Complication 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Cardiac Imaging Procedure Abnormal 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Malignant Melanoma In Situ 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Suicide Attempt 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Abdominal pain 3/116 (2.59%) secondary trial: Dyspnoea 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Ascites 1/116 (0.86%) secondary trial: Total: 8/54 (14.81%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af | primary trial: Ascites 1/116 (0.86%) secondary trial: Anaemia 1/54 (1.85%) There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | 1 |